Latest news on COVID-19 and PIDs

IPOPI is committed to monitor closely the COVID-19 pandemic and to share evidence-based and expert validated information to the global primary immunodeficiency (PID) patients community and to our stakeholders.

The situation is evolving rapidly all over the world with new restrictions being imposed in an increasing number of countries. Our priority is the safety of all PID patients and the safety of supply of their life-saving treatments both during and after the COVID-19 pandemic. IPOPI has been engaging on several fronts to fast track the publication of statements, answer frequently asked questions and participate in international efforts to collect data on COVID-19 in PIDs.

This page aggregates all of IPOPI’s efforts and selected external statements.

COVID-19 Statements

IPOPI commits to publish and update its statements as the situation evolves. Please always refer to the latest statement which contains up to date recommendations.

Recommendations: Monoclonal antibodies, Vaccination for PID patients

COVID-19 and PIDs FAQs

COVID-19 Learning Expedition Report released

Policy Actions

Article

Global Survey on COVID-19 and PIDs (for physicians)

Global Survey on COVID-19 and PIDs (for physicians)

IPOPI is participating in the launch of a global survey on COVID-19 and PIDs, working jointly with International Union of Immunological Societies (IUIS) and other medical societies.

The survey is now entering phase 2 – please help us by sharing it with national medical advisers and all national doctors who you know are managing PID patients in your country:

External materials

Please find external helpful resources and updated information on the COVID-19 outbreak.

Copyright © 2021 IPOPI. All Rights Reserved.